Platelet-derived Growth Factor Receptor-α as a Biomarker for Tongue Spindle Cell Carcinoma

  • 0Department of Dentistry and Oral Surgery, Keio University School of Medicine, Tokyo, Japan; takehitoo@tdc.ac.jp.

|

|

Summary

This summary is machine-generated.

Mesenchymal stem/stromal cells (MSCs), particularly those expressing PDGFRα, expand in spindle cell carcinoma (SpCC) and may drive epithelial-mesenchymal transition. Targeting PDGFRα could offer new therapeutic strategies for this aggressive cancer.

Area Of Science

  • Oncology
  • Cancer Biology
  • Stem Cell Research

Background

  • Spindle cell carcinoma (SpCC) is a rare, aggressive squamous cell carcinoma subtype with unclear characteristics and a poor prognosis.
  • Effective treatment strategies for SpCC require specialized approaches distinct from conventional squamous cell carcinoma treatments.

Purpose Of The Study

  • To investigate the distribution and role of mesenchymal stem/stromal cells (MSCs), specifically PDGFRα-expressing MSCs, within SpCC.
  • To explore the potential involvement of MSCs in epithelial-mesenchymal transition (EMT) in SpCC.

Main Methods

  • Immunohistological analysis of tissue sections to detect immunopositive signals for MSC markers, including PDGFRα.
  • Examining the spatial relationship between MSCs and cancer epithelial cells (EpCAM-positive).

Main Results

  • An expansion of PDGFRα-positive MSCs and other MSC markers was observed within SpCC tissue.
  • MSCs were found adjacent to EpCAM-positive cancer epithelial cells.
  • Some EpCAM-positive cells were surrounded by cancer-associated fibroblasts and showed MSC marker positivity.

Conclusions

  • MSC expansion, particularly PDGFRα-positive MSCs, is associated with EpCAM-positive areas in SpCC.
  • MSCs may function as cancer niche elements promoting EMT in SpCC.
  • Targeting PDGFRα presents a potential therapeutic avenue for SpCC, aiding in understanding tumor biology and developing novel treatments.

Related Concept Videos